Whitepaper: Redefining the ‘S’ in ESG with Gilead
ESG issues are currently at the forefront of investment decisions. Yet, they’re also facing unprecedented political scrutiny. While some companies see ESG as a risk management exercise that can reduce returns, others, like biopharmaceutical company Gilead, are embedding ESG into their value chain, core business operations and driving value for the communities they serve. 

As Sherry Glied, Dean of New York University’s Robert F. Wagner Graduate School of Public Service points out:

“Companies can choose to target diseases that most affect high-income people or those that mostly affect those on lower incomes… For the good of the world, we should be spending more money on diseases that affect a lot of people who are not rich.”

In partnership with Gilead, we’ve produced a whitepaper looking at a case study in purpose-driven ESG integration. Understand how Gilead Sciences are addressing unmet needs, ensuring health equity and partnering with communities to promote a holistic approach to healthcare. 
The Whitepaper covers:

  • The dichotomy between the U.S’ voluntary approach to ESG and the EU’s regulatory integration
  • How diversifying clinical trials addresses disparities in underserved populations
  • How ESG adds intrinsic value to strategic planning and long-term investments.
  • How voluntary licensing enhances healthcare access by facilitating knowledge transfer and fostering local manufacturing capabilities
If you have any feedback about this whitepaper or the topic it was produced in conjunction with don’t hesitate to get in touch with christian.hickmott@thomsonreuters.com. We hope you find it to be informative reading.

Best,
Christian

Christian Hickmott
Project Director
Reuters Events

Telephone: +44 20 3197 8053
Download the briefing now!
Simply fill in your details below to receive the briefing.
Reuters Events will use this information to contact you about relevant content, products, and services. You may unsubscribe at any time. For more information, check out our Privacy Policy: https://www.thomsonreuters.com/en/privacy-statement.html.
Please tick this box to give Reuters Events permission to provide my contact information to Gilead - https://www.gilead.com/ - so Gilead can share the latest Gilead news and offers with me by email or telephone.
You may unsubscribe from receiving news and offers from the sender at any time by following the instructions in the communications received. Intralinks handles your information as described in the Intralinks privacy notice -https://www.gilead.com/privacy-statements
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.